Lauder Partners — 2026 Investments
2 investments dated 2026 · listed companies and verified rows first · show all
Georgiamune is a biopharmaceutical company developing targeted immunomodulator drugs that activate or down-modulate immune signaling pathways to treat cancer and autoimmune diseases.
BiotechDeep TechHealthtechGaithersburg, US
Samir N. Khleif(Founder & CEO)Ramy Ibrahim(Chief Medical and Strategy Officer)Mikayel Mkrichyan(Senior Vice President of Science and Discovery)Sarah Sharman(Vice President of IP Legal Affairs)
BoardSean Parker(Director)Elena Viboch(Director)
PartnerGary Lauder· solo GP
Co-investorsCatalio Capital Management, LPHAWKTAILPrevail Venture CapitalGeneral CatalystJohnson & Johnson Innovation – JJDC
Solius makes an FDA-cleared, over-the-counter UVB light therapy device that analyzes a user's skin tone to deliver a personalized dose of UVB light for vitamin D production and other systemic health benefits.
HealthtechMedical DevicesWellness & FitnessBainbridge Island, US
Chris Kiple(Executive Officer, Director)inRobert Wise(Executive Officer)David Good(Executive Officer)Alexander Moffat(Executive Officer, Director, Promoter)Rick Hennessey(Executive Officer, Director, Promoter)Dave Good(Chief Special Projects Officer)
PartnerGary Lauder· solo GP
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.